Gangtok Chronicle

DelveInsight’s “Chronic Spontaneous Urticaria Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of chronic spontaneous Urticaria, historical and forecasted epidemiology, as well as the chronic spontaneous Urticaria market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

 

Key Takeaways from the Chronic Spontaneous Urticaria Market Research Report

• The increase in Chronic Spontaneous Urticaria Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Chronic Spontaneous Urticaria Market is anticipated to witness growth at a considerable CAGR.
• As per DelveInsight analysis, there were approximately 4,154,234 total Chronic Spontaneous Urticaria diagnosed prevalent cases in the 7MM, in 2022. These cases are projected to increase during the forecast period (2023-2034).
• As per DelveInsight analysis among EU4 and the UK, there was a higher female affected population for e.g. Germany accounted for around 97,142 male and 229,935 females affected from CSU in 2022. These cases are expected to change during the forecast period (2023-2034).
• The leading Chronic Spontaneous Urticaria Companies working in the market include Novartis, Sanofi Pharmaceutical, Genentech, AstraZeneca, Kiniksa Pharmaceuticals, Ltd, United BioPharma, GlaxoSmithKline, Allakos, Eli Lilly and Company and others.
• Promising Chronic Spontaneous Urticaria Pipeline Therapies in the various stages of development include Dupilumab SAR231893, CT-P39, EU-approved Xolair, Ligelizumab, Oral EP262, and others.
• April 2024:- Escient Pharmaceuticals, Inc announced a study of Phase 2 clinical trials for Oral EP262. Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects with Chronic Spontaneous Urticaria.
• April 2024:- Sanofi- Master Protocol of Three Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naïve to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab.

 

Discover which therapies are expected to grab the Chronic Spontaneous Urticaria Market Share @ Chronic Spontaneous Urticaria Market Outlook

 

Chronic Spontaneous Urticaria Overview

Urticaria is a common and heterogeneous inflammatory skin disorder with or without associated angioedema. It presents with wheals, angioedema, or both due to activation and degranulation of skin mast cells, followed by the release of histamine and other mediators leading to sensory nerve activation, vasodilatation, plasma extravasation, and cellular recruitment. It is classified as acute or chronic, depending on whether the onset of episodes lasts for less or >6 weeks, respectively.

 

Chronic Spontaneous Urticaria Epidemiology Insights

The epidemiology section of Chronic Spontaneous Urticaria offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

• Total Chronic Spontaneous Urticaria Diagnosed Prevalent Cases
• Chronic Spontaneous Urticaria Type-specific Cases
• Chronic Spontaneous Urticaria Gender-specific Cases
• Chronic Spontaneous Urticaria Age-specific Cases
• Chronic Spontaneous Urticaria Severity-specific Cases

 

Download the report to understand which factors are driving Chronic Spontaneous Urticaria Epidemiology trends @ Chronic Spontaneous Urticaria Epidemiological Insights

 

Chronic Spontaneous Urticaria Drugs Market

The Chronic Spontaneous Urticaria Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Chronic Spontaneous Urticaria signaling in Chronic Spontaneous Urticaria are likely to uncover new therapeutic targets and further expand treatment options for patients.

 

Chronic Spontaneous Urticaria Treatment Market Landscape

Chronic Spontaneous Urticaria treatment is generally initiated with no sedating antihistamines in the daytime and sedating antihistamines at night. H2-antihistamines are often combined with H1 to achieve better symptom control in CSU and are added if individuals complain of indigestion or acidity. The most commonly used H2 antihistamine for CSU is ranitidine.

 

To know more about Chronic Spontaneous Urticaria treatment guidelines, visit @ Chronic Spontaneous Urticaria Treatment Market Landscape

 

Chronic Spontaneous Urticaria Market Outlook

The report’s outlook on the Chronic Spontaneous Urticaria market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Chronic Spontaneous Urticaria therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Chronic Spontaneous Urticaria drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Chronic Spontaneous Urticaria market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

 

Chronic Spontaneous Urticaria Drugs Uptake

 

Remibrutinib (LOU064): Novartis Pharmaceuticals

Remibrutinib is an oral treatment that potently and selectively inhibits bruton’s tyrosine kinase (BTK) enzyme, which plays a critical role in the inflammatory activity of certain immune cells, such as B cells and microglia. Remibrutinib inhibits degranulation induced by IgE cross-linking in mast cells and basophils and the activation triggered by factors present in the sera of spontaneous and inducible chronic urticaria patients. Recently, in its Phase III REMIX-1 and REMIX-2 trials, the drugs showed clinically meaningful and statistically significant reduction in weekly urticaria activity (UAS7), itch (ISS7) and hives (HSS7) at Week 12 compared to placebo. Remibrutinib was well-tolerated and demonstrated a favorable safety profile with rates of overall adverseevents comparable to placebo and balanced liver function tests across both studies. Studies are ongoing with final readout and regulatory submissions anticipated in 2024.

 

DUPIXENT (dupilumab): Sanofi/Regeneron

DUPIXENT is a human monoclonal IgG4 antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling by specifically binding to the IL-4Rα subunit shared by the IL-4 and IL-13 receptor complexes. Dupilumab inhibits IL-4 signaling via the ‘Type I’ receptor and both IL-4 and IL-13 signaling through the ‘Type II’ receptor. Multiple cell types that express IL-4Rα. DUPIXENT is approved for multiple indications, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), eosinophilic esophagitis, and prurigo nodularis. In July 2021, the Phase III trial met its primary and key secondary endpoints at 24 weeks, showing DUPIXENT nearly doubled reduction in itch and urticaria activity scores. Sanofi and Regeneron files and sNDA for DUPIXENT in chronic spontaneous urticaria, for which the US FDA issues a CRL stating that additional efficacy data is required to support an approval. The drug is currently investigated in Phase III trials in patients naïve to omalizumab or intolerant or incomplete responders to omalizumab, with results expected in late 2024 for DUPIXENT in CSU in biologic-naïve patients.

 

TEZSPIRE (tezepelumab): AstraZeneca/Amgen

TEZSPIRE (tezepelumab [AMG 157]) is being developed by AstraZeneca in collaboration with Amgen as a first-in-class human monoclonal antibody that inhibits the action of blocks thymic stromal lymphopoietin (TSLP), a key epithelial cytokine that sits at the top of multiple inflammatory cascades and is critical in the initiation and persistence of allergic, eosinophilic and airway inflammation diseases. TSLP, IL-25, and IL-33 are released following different triggers on epithelia and start the Th2 inflammatory response, mediating T-cell polarization in Th2 cells. Tezepelumab, with its inhibitory action of TSLP, appears to prevent and treat the lesional skin of patients with CSU. TEZSPIRE is currently approved for treating severe asthma in the US, EU, Japan, and other countries. Moreover, TEZSPIRE is approved in the US for the add-on maintenance treatment of adult and pediatric patients aged 12 and older with severe asthma. TEZSPIRE is in development for CSU (Phase II completed) and other potential indications, including COPD, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis.

 

Major Chronic Spontaneous Urticaria Companies

Several Chronic Spontaneous Urticaria Companies working in the market include Novartis, Sanofi Pharmaceutical, Genentech, AstraZeneca, Kiniksa Pharmaceuticals, Ltd, United BioPharma, GlaxoSmithKline, Allakos, Eli Lilly and Company and others.

 

Learn more about the FDA-approved drugs for Chronic Spontaneous Urticaria @ Drugs for Chronic Spontaneous Urticaria Treatment

 

Scope of the Chronic Spontaneous Urticaria Market Research Report

• Coverage- 7MM
• Chronic Spontaneous Urticaria Companies- Novartis, Sanofi Pharmaceutical, Genentech, AstraZeneca, Kiniksa Pharmaceuticals, Ltd, United BioPharma, GlaxoSmithKline, Allakos, Eli Lilly and Company and others.
• Chronic Spontaneous Urticaria Therapies- Dupilumab SAR231893, CT-P39, EU-approved Xolair, Ligelizumab, Oral EP262, and others.
• Chronic Spontaneous Urticaria Market Dynamics: Chronic Spontaneous Urticaria Market Drivers and Barriers
• Chronic Spontaneous Urticaria Market Access and Reimbursement, Unmet Needs and Future Perspectives

 

Discover more about Chronic Spontaneous Urticaria Drugs in development @ Chronic Spontaneous Urticaria Clinical Trials Assessment

 

Table of Content

1. Key Insights

2. Report Introduction

3. Chronic Spontaneous Urticaria Market Overview at a Glance

4. Methodology of Chronic Spontaneous Urticaria Epidemiology and Market

5. Executive Summary of Chronic Spontaneous Urticaria

6. Key Events

7. Disease Background and Overview

8. Patient Journey

9. Epidemiology and Patient Population

10. Marketed Drugs

11. Emerging Drugs

12. Chronic Spontaneous Urticaria: Market Analysis

13. Key Opinion Leaders’ Views

14. SWOT

15. Unmet needs

16. Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/